32 / 32
•
Progressive redefinition of a precision medicine framework
•
Innovative trial designs
•
Evaluation and approval of new drugs in small cohorts of orphan cancers
•
New clinical, regulatory and reimbursement challenges
•
Agnostic-histology approvals will continue to grow